{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wong KSL"],"funding":["NINDS NIH HHS"],"pagination":["1678-1685"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6019568"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["49(7)"],"pubmed_abstract":["<h4>Background and purpose</h4>SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (<i>P</i>=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization.<h4>Methods</h4>A prespecified subgroup analysis in SOCRATES (n=13 199), randomizing patients with acute ischemic stroke (National Institutes of Health Stroke Sc"],"journal":["Stroke"],"pubmed_title":["Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial."],"pmcid":["PMC6019568"],"funding_grant_id":["U01 NS062835"],"pubmed_authors":["Knutsson M","Johnston SC","Molina CA","Ladenvall P","Easton JD","Evans SR","Himmelmann A","Amarenco P","Albers GW","Kasner SE","Minematsu K","SOCRATES Steering Committee and Investigators","Denison H","Held P","Wang Y","Wong KSL"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial.","description":"<h4>Background and purpose</h4>SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (<i>P</i>=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization.<h4>Methods</h4>A prespecified subgroup analysis in SOCRATES (n=13 199), randomizing patients with acute ischemic stroke (National Institutes of Health Stroke Sc","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2026-04-14T13:23:32.257Z","creation":"2026-04-07T13:42:39.324Z"},"accession":"S-EPMC6019568","cross_references":{"pubmed":["29915123"],"doi":["10.1161/STROKEAHA.118.020553","10.1161/strokeaha.118.020553"]}}